OncoSec to Present at the LD 500 Virtual Conference on September 2, 2020
OncoSec Medical (NASDAQ:ONCS) announced that CEO Daniel J. O'Connor will present at the LD 500 Virtual Conference on September 2, 2020, at 10:00 a.m. ET. The presentation will include a live Q&A session with investors. The conference runs from September 1-4, 2020, with O'Connor available for one-on-one meetings. OncoSec is focused on developing intratumoral cancer immunotherapies, particularly utilizing its lead candidate, TAVO™, to enhance immune response against tumors. More details can be found on OncoSec's investor website.
- None.
- None.
SAN DIEGO and PENNINGTON, N.J., Aug. 25, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer will present at the LD 500 Virtual Conference on Wednesday, September 2, 2020.
The presentation will begin September 2, 2020 at 10:00 a.m. eastern time, Track 3, followed by a live Q&A session with registered investors and other conference attendees. The OncoSec presentation will be webcast at https://www.webcaster4.com/Webcast/Page/2019/36144, and will be available on the Investors section of OncoSec's website, https://ir.oncosec.com, where it will be archived for approximately 30 days.
The virtual conference and presentations will be held via webcast from September 1 – 4, 2020 and Mr. O'Connor will be available for virtual one-on-one meetings throughout. To schedule a meeting, please contact Eric Lahiji at eric@ldmicro.com.
About OncoSec Medical Incorporated
OncoSec Medical Incorporated is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead product candidate, TAVO™, enables the intratumoral delivery of DNA-based interleukin-12 or IL-12, a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors. The company is currently evaluating TAVO in combination with the anti-PD-1 checkpoint inhibitor, KEYTRUDA® (pembrolizumab), in two KEYNOTE clinical trials, including a pivotal trial in patients with anti-PD-1 checkpoint resistant metastatic melanoma and a phase 2 trial in metastatic triple negative breast cancer. OncoSec is also identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its novel Visceral Lesion Applicator designed to target deep internal lesions, such as liver, lung or pancreatic lesions. For more information, please visit www.oncosec.com.
TAVO™ is a trademark of OncoSec Medical Incorporated.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Risk Factors and Forward-Looking Statements
This release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company's current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company's control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and "would" and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission ("SEC"). In particular, you should be aware that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, the impact of COVID-19 on the supply of our candidates or the initiation or completion of clinical trials and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC's website www.sec.gov), as well as other factors described from time to time in the Company's filings with the SEC.
Company Contact:
Kellie Malloy
Chief Operating Officer
855.662.6732
kmalloy@oncosec.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-at-the-ld-500-virtual-conference-on-september-2-2020-301117502.html
SOURCE OncoSec Medical Incorporated
FAQ
What is OncoSec's presentation at the LD 500 Virtual Conference about?
When is the LD 500 Virtual Conference presentation by OncoSec?
How can I access OncoSec's presentation at the LD 500 Virtual Conference?
What is TAVO™ and its significance for OncoSec?
Which clinical trials is OncoSec currently undertaking with TAVO™?
